The Lancet Diabetes & Endocrinology最新文献

筛选
英文 中文
The need for improved diabetes detection and treatment. 需要改进糖尿病的检测和治疗。
IF 41.8 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-11-01 Epub Date: 2025-09-09 DOI: 10.1016/S2213-8587(25)00250-5
Henrik Toft Sørensen
{"title":"The need for improved diabetes detection and treatment.","authors":"Henrik Toft Sørensen","doi":"10.1016/S2213-8587(25)00250-5","DOIUrl":"10.1016/S2213-8587(25)00250-5","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"899-901"},"PeriodicalIF":41.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global, regional, and national cascades of diabetes care, 2000-23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study. 2000-23年全球、区域和国家糖尿病护理级联:使用全球疾病负担研究结果的系统回顾和建模分析
IF 41.8 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-11-01 Epub Date: 2025-09-09 DOI: 10.1016/S2213-8587(25)00217-7
Lauryn K Stafford, Anna Gage, Yvonne Yiru Xu, Madeleine Conrad, Ismael Barreras Beltran, Edward J Boyko, Bruce B Duncan, Simon I Hay, Hailey Lenox, Rafael Lozano, Dianna J Magliano, Carlos A Aguilar Salinas, Nikhil Tandon, Pedro Zitko, Christopher J L Murray, Theo Vos, Annie Haakenstad, Kanyin Liane Ong
{"title":"Global, regional, and national cascades of diabetes care, 2000-23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study.","authors":"Lauryn K Stafford, Anna Gage, Yvonne Yiru Xu, Madeleine Conrad, Ismael Barreras Beltran, Edward J Boyko, Bruce B Duncan, Simon I Hay, Hailey Lenox, Rafael Lozano, Dianna J Magliano, Carlos A Aguilar Salinas, Nikhil Tandon, Pedro Zitko, Christopher J L Murray, Theo Vos, Annie Haakenstad, Kanyin Liane Ong","doi":"10.1016/S2213-8587(25)00217-7","DOIUrl":"10.1016/S2213-8587(25)00217-7","url":null,"abstract":"<p><strong>Background: </strong>Diabetes is a serious global health challenge, with a rising prevalence and substantial effect on disability and mortality worldwide. Despite medical advancements, gaps in the cascade of diabetes care-comprising diagnosis, treatment, and glycaemic management-persist, hindering effective management. We aimed to comprehensively assess the state of the diabetes cascade of care globally, identifying areas of strength and needs for improvement in diabetes management.</p><p><strong>Methods: </strong>Using data and methods from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), this modelling analysis spanned the years 2000 to 2023 and covered 204 countries and territories. We systematically reviewed cross-sectional surveys that are representative of the general population and the published and grey literature to estimate the proportion of people with diabetes who are undiagnosed, diagnosed but untreated, receiving treatment with suboptimal glycaemic concentrations, and receiving treatment with optimal glycaemic concentrations. Treatment was defined as current use of insulin or other hypoglycaemic medication. We separately modelled these quantities by location, year, age, and sex using DisMod-MR 2.1, a hierarchical Bayesian meta-regression modelling tool, then scaled the estimates so that they sum to 100% of people living with diabetes in each stratum. Using GBD 2023 estimates of the number of people with diabetes, we calculated the diabetes cascade of care: proportion of people diagnosed among those with diabetes, proportion of people receiving treatment among those with diagnosed diabetes, and proportion of people with optimal glycaemic concentrations among those receiving treatment for diabetes across all strata.</p><p><strong>Findings: </strong>In 2023, an estimated 55·8% (95% UI 49·3-62·3) of people with diabetes aged 15 years and older were diagnosed with diabetes globally. The proportion of people with diagnosed diabetes who were on treatment was 91·4% (88·0-94·2), and the proportion of people on diabetes treatment with optimal glycaemic concentrations was 41·6% (35·7-48·5). Among all people with diabetes, the proportion with optimal glycaemic concentrations on treatment was 21·2% (17·4-25·6) in 2023 globally. Substantial regional differences were observed, with the highest rates of diagnosis in high-income North America, the highest rates of treatment among those with diagnosed diabetes in high-income Asia Pacific, and the highest rates of optimal glycaemic concentrations among those receiving treatment for diabetes in southern Latin America. Between 2000 and 2023, globally, the proportion of people diagnosed with diabetes increased by 8·3 (6·6-10·0) percentage points, and the proportion of people receiving treatment among those diagnosed increased by 7·2 (5·7-8·8) percentage points. The proportion of people receiving treatment who had optimal glycaemic concentrations increased by 1·3 (0·8-1·8)","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"924-934"},"PeriodicalIF":41.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Diabetes Endocrinol 2022; 10: 623–33 《柳叶刀糖尿病内分泌》2022版修正;10: 623 - 33所示
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-15 DOI: 10.1016/s2213-8587(25)00325-0
{"title":"Correction to Lancet Diabetes Endocrinol 2022; 10: 623–33","authors":"","doi":"10.1016/s2213-8587(25)00325-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00325-0","url":null,"abstract":"<em>Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.</em> Lancet Diabetes Endocrinol <em>2022;</em> 10: <em>623–33</em>—Appendix 2 of this Article has been corrected as of Oct 15, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"67 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145295654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing educational needs in older adults with type 1 diabetes 解决老年1型糖尿病患者的教育需求
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-14 DOI: 10.1016/s2213-8587(25)00259-1
Giuseppe Maltese, Partha Kar, Geraldine Gallen, Debbie Hicks, Alan J Sinclair
{"title":"Addressing educational needs in older adults with type 1 diabetes","authors":"Giuseppe Maltese, Partha Kar, Geraldine Gallen, Debbie Hicks, Alan J Sinclair","doi":"10.1016/s2213-8587(25)00259-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00259-1","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"13 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework 管理筛查检测到胰岛自身抗体阳性的成人:一个实用的框架
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-14 DOI: 10.1016/s2213-8587(25)00260-8
Nicholas Thomas, Danijela Tatovic, Angus Jones, Parth Narendran
{"title":"Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework","authors":"Nicholas Thomas, Danijela Tatovic, Angus Jones, Parth Narendran","doi":"10.1016/s2213-8587(25)00260-8","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00260-8","url":null,"abstract":"New disease-modifying therapies, such as teplizumab, offer opportunities to delay the clinical onset of type 1 diabetes but require islet autoantibody screening to identify individuals at increased risk of progression to diabetes. As type 1 diabetes screening programmes expand, clinicians will increasingly encounter a new group of people: adults who test positive for islet autoantibodies but have not yet been diagnosed with diabetes. Although international guidelines outline management for both children and adults, considerable uncertainties remain, particularly for adults. In adults with islet autoantibody positivity, the lower risk of progression to type 1 diabetes compared with children, combined with the high background prevalence of mild non-autoimmune dysglycaemia, presents substantial challenges for clinical management. This Personal View aims to add clarity to international consensus guidelines, proposing a pragmatic framework for managing adults with islet autoantibody positivity. Although fitting within a UK National Health Service setting, we feel this framework is also relevant to other health systems.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"9 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis 恩格列净对常规和探索性急慢性肾脏结局的影响:个体参与者水平的荟萃分析
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-11 DOI: 10.1016/s2213-8587(25)00222-0
William G Herrington, Zhaojing J Che, Rebecca Sardell, Alistair J Roddick, Parminder K Judge, Christoph Wanner, Sibylle J Hauske, Stefan Anker, Javed Butler, Gerasimos Filippatos, Milton Packer, Faiez Zannad, Dominik Steubl, Martina Brueckmann, Jennifer B Green, Jonathan R Emberson, Martin J Landray, Colin Baigent, Richard Haynes, Natalie Staplin
{"title":"Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis","authors":"William G Herrington, Zhaojing J Che, Rebecca Sardell, Alistair J Roddick, Parminder K Judge, Christoph Wanner, Sibylle J Hauske, Stefan Anker, Javed Butler, Gerasimos Filippatos, Milton Packer, Faiez Zannad, Dominik Steubl, Martina Brueckmann, Jennifer B Green, Jonathan R Emberson, Martin J Landray, Colin Baigent, Richard Haynes, Natalie Staplin","doi":"10.1016/s2213-8587(25)00222-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00222-0","url":null,"abstract":"<h3>Background</h3>Uncertainty remains about effects of sodium–glucose co-transporter-2 (SGLT2) inhibition on kidney outcomes in individuals with slowly progressive chronic kidney disease (eg, low albuminuria) and those at risk of large acute estimated glomerular filtration rate (eGFR) dips on initiation of such treatment. We aimed to explore the effects of empagliflozin on a range of kidney outcomes in these population subtypes.<h3>Methods</h3>In this meta-analysis, we used individual-level data from 23 340 participants in four large placebo-controlled trials (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY) to assess the effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes. We then assessed whether effects varied by predicted size of the acute eGFR dip on treatment initiation or among other key population subtypes using tests for heterogeneity and trend. The individual-level data were requested from Boehringer Ingelheim (Ingelheim, Germany).<h3>Findings</h3>Compared with placebo, allocation to empagliflozin reduced the risk of a marker of acute kidney injury (a ≥50% increase in serum creatinine in consecutive follow-up samples) by 20% (hazard ratio 0·80 [95% CI 0·72–0·88]; 1573 outcomes), acute kidney injury adverse events by 27% (0·73 [0·63–0·85]; 694 outcomes), a categorical chronic kidney disease progression outcome by 30% (0·70 [0·63–0·78]; 1403 outcomes), and kidney failure by 34% (0·66 [0·55–0·79]; 490 outcomes). Empagliflozin slowed a chronic annual rate of eGFR decline by 64% (95% CI 59–69) and off-treatment dip-free slope—a post-hoc outcome using randomisation and off-treatment eGFR values available in a subset of 10 630 participants—by 64% (54–73). These kidney benefits were similar in subgroups divided by predicted size of acute eGFR dip, and were present irrespective of diabetes or heart failure status, level of kidney function, or albuminuria.<h3>Interpretation</h3>SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status, primary cause of kidney disease, and markers of severity of these diseases.<h3>Funding</h3>None.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"52 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use 恩格列净在慢性肾病中的应用:早期、全面和自信使用的证据
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-11 DOI: 10.1016/s2213-8587(25)00224-4
Carmine Zoccali, Francesca Mallamaci
{"title":"Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use","authors":"Carmine Zoccali, Francesca Mallamaci","doi":"10.1016/s2213-8587(25)00224-4","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00224-4","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"104 5 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Has the WHO Model Essential Medicines List lost its way? 世卫组织基本药物标准清单是否迷失了方向?
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-07 DOI: 10.1016/s2213-8587(25)00292-x
David Beran, Amanda Adler, Carol Abidha, Naomi Levitt, Nikhil Tandon, Janeth Tenorio Mucha, John S Yudkin, Stephen Colagiuri
{"title":"Has the WHO Model Essential Medicines List lost its way?","authors":"David Beran, Amanda Adler, Carol Abidha, Naomi Levitt, Nikhil Tandon, Janeth Tenorio Mucha, John S Yudkin, Stephen Colagiuri","doi":"10.1016/s2213-8587(25)00292-x","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00292-x","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"5 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula 阿拉伯半岛2型糖尿病流行的进化基础
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-10-03 DOI: 10.1016/s2213-8587(25)00294-3
Hamad Ali, Barrak Alahmad, Mohamed Abu-Farha, Jehad Abubaker, Fahd Al-Mulla
{"title":"The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula","authors":"Hamad Ali, Barrak Alahmad, Mohamed Abu-Farha, Jehad Abubaker, Fahd Al-Mulla","doi":"10.1016/s2213-8587(25)00294-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00294-3","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"54 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peripheral CB1 receptor blockade for treatment of obesity 外周CB1受体阻断治疗肥胖
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-09-29 DOI: 10.1016/s2213-8587(25)00255-4
Kishore M Gadde, Jonanne Talebloo, Daniele Piomelli
{"title":"Peripheral CB1 receptor blockade for treatment of obesity","authors":"Kishore M Gadde, Jonanne Talebloo, Daniele Piomelli","doi":"10.1016/s2213-8587(25)00255-4","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00255-4","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"53 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信